Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rheumatoid Arthritis: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs

NCT03682705 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03682705
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03682705 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rheumatoid Arthritis: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599 Combination) With a Background of Conventional Synthetic DMARDs in Subjects With Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
October 8, 2018
Completion date
March 26, 2020
Enrollment
242 (actual)
Sites
115

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra)